The positive trial results for STAR-0215 indicate a significant advancement in the treatment of HAE, a rare condition. This development is likely to be viewed positively by investors, as it not only demonstrates the company's R&D capabilities but also sets the stage for potential future revenue growth through successful Phase 3 trials and eventual product commercialization. The announcement of moving to Phase 3 development is a critical milestone, suggesting confidence in the drug's efficacy and safety profile.